Introduction: Several nuclear receptor family members have been associated with schizophrenia and inflammation. Vitamins A and D exert anti-inflammatory actions, but their receptors (mainly nuclear receptors) have not been extensively studied in either schizophrenia brains or in association with neuroinflammation. We examined the expression of vitamin A (RARs and RXRs) and vitamin D and protein disulphide-isomerase A3 (PDIA3) receptors, as well as nuclear orphan receptors (NR4As), in the context of elevated cytokine expression in the dorsolateral prefrontal cortex (DLPFC). Methods: mRNA levels of nuclear receptors were measured in DLPFC tissues via RT-qPCR. ANCOVAs comparing high inflammation schizophrenia, low inflammation schizophrenia and low inflammation control groups were performed. Results: RARG, RXRB, NR4A1 and NR4A3 transcripts showed significant differential expression across the three groups (ANCOVA p = 0.02-0.001). Post hoc testing revealed significant reductions in RARG expression in schizophrenia with low inflammation compared to schizophrenia with high inflammation and to controls, and RXRB mRNA was significantly reduced in schizophrenia with low inflammation compared to controls. NR4A1 and NR4A3 mRNAs were decreased in schizophrenia with high inflammation compared to schizophrenia with low inflammation, with NR4A1 also significantly different to controls. Conclusion: In schizophrenia, changes in nuclear receptor mRNA levels involved with mediating actions of vitamin A derivatives vary according to the inflammatory state of brains.
Introduction
Schizophrenia is a debilitating mental illness affecting approximately 1% of the world's population. Whilst the primary cause is still uncertain, many genetic polymorphisms and environmental perturbations have been implicated in increased risk of schizophrenia. One of the main molecular mechanisms whereby genes and environments converge to mediate risk is in the control of gene expression. Several transcription factors are altered in the brains of people with schizophrenia, including DOI: 10.1159/000485565 members of the nuclear receptor superfamily, such as the expression of oestrogen receptor mRNA [1, 2] , and the mRNA and protein levels of the glucocorticoid receptor [3, 4] . Changes in ligands (low oestrogen levels and increased stress hormone) appear to exaggerate symptoms of schizophrenia [5] [6] [7] [8] . Vitamin D is another ligand with brain responsive nuclear receptors, and both very low and very high prenatal exposure to vitamin D is associated with a two-fold increased risk of later developing schizophrenia or schizophrenia-like behaviour [9] [10] [11] . However, despite compelling evidence of the neurodevelopmental role of vitamin D [9] , the extent to which vitamin D receptors (VDRs) may be altered in the brain of people who have already developed schizophrenia has not been examined.
Epidemiological studies have shown that maternal malnourishment and vitamin deficiencies due to famine lead to an increased risk of schizophrenia in the offspring [12, 13] . Additionally, higher rates of schizophrenia are observed amongst people born in winter and spring, though the associated higher rates of maternal infection in these seasons and vitamin D deficiency due to reduced sunlight cannot easily be disentangled [14] . Low levels of vitamin D could be caused by a number of factors, including dietary insufficiency, reduced exposure to sunlight [14] , or reduced enzyme activity of 1α-hydroxylase, the enzyme responsible for formation of the active vitamin [15] . In addition to these perinatal risk factors, low circulating vitamin D levels have been found in people with schizophrenia [19] , and associated with symptom severity [20] and with general decreased cognitive function in adulthood [21, 22] and it is possible that abnormalities extend to include VDRs in the brain. To our knowledge, there have been no studies examining the expression of VDR in the brains of people with schizophrenia to date.
There are two types of VDRs: the cytosolic/nuclear VDR, and the VDR at the cell membrane, which is a rapid response steroid-binding receptor, also known as the protein disulphide-isomerase A3 (PDIA3). Both vitamin D and VDR have been shown to have neuroprotective qualities [23] [24] [25] . VDR is expressed in both glia and neurons in numerous regions of the human brain including the prefrontal cortex [15] . VDR is predominantly present in the cytoplasm. Once bound by vitamin D, the complex translocates to the nucleus where it acts to increase or decrease gene expression [26] . Once the membrane form of VDR, PDIA3, is bound by vitamin D [27] , PDIA3 elicits a fast uptake of calcium and phosphorus into cells [28] . Few studies have directly examined genetic association between VDR or PDIA3 and schizophrenia, and these have been of very limited sample size (i.e., <200 cases) [29] [30] [31] . More recently, a genome-wide association study of nearly 37,000 individuals with schizophrenia [32] provides significant evidence of association of a locus on chromosome 6 containing the retinoid X receptor B gene (RXRB), as well as nominal evidence of association of a number of other retinoid receptor genes including RARG, VDR, and PDIA3 (p < 6.8E-5). Thus, it is possible that interactions between genetic risk variants and environmental exposures, which are thus far poorly studied, result in disrupted receptor signalling and increased risk of schizophrenia.
VDR can heterodimerise with other nuclear receptors and mediate transcriptional controls through binding to vitamin A receptors (retinoid receptors), and through binding to direct nucleotide sequences [33] and DNA response elements [34] . Retinoic acid is a derivative of vitamin A and it is important for growth, differentiation, and homeostasis within the brain [35] and may have neuroprotective actions after brain trauma [36] [37] [38] . The three members of the retinoic acid receptor family (RARA, RARB, and RARG) have highly similar structures and bind to all-trans retinoic acid, the active form of vitamin A [39, 40] . In contrast, the three retinoid X receptors (RXRA, RXRB, and RXRG) are indirectly activated by all-trans retinoic acid, but do not directly bind the ligand [39, 40] . VDR can dimerise with RXRs to regulate transcription, and VDR has been shown to dimerise more readily to RXRA than to the other RXRs [41, 42] .
We have previously found RXRB mRNA, as well as another group of nuclear receptor superfamily members, NR4A1 and NR4A2, to be decreased in schizophrenia patients compared to controls [43] . Extending from our previous study, we now investigated the possible relationship these decreases may have to any putative change in VDRs, and to markers of inflammation. We previously found a subset of individuals with schizophrenia with elevated expression of a number of inflammatory markers in the dorsolateral prefrontal cortex (DLPFC) [44, 45] and the orbital frontal cortex [46] , which we have termed a "high neuroinflammation" group. Further, we demonstrated that increased cytokines are associated with elevated microglia density [44] and reduced grey matter volume in the frontal cortex [46] of individuals with schizophrenia. This is consistent with previous studies showing that maternal immune activation predisposes to schizophrenia [47, 48] and increased activated microglia, a key source of cytokines in the brain, in people with schizoNuclear Receptors and Neuroinflammation phrenia [49, 50] . As vitamin D and vitamin A possess anti-inflammatory properties, and as nuclear receptor family members have reduced expression in the context of neuroinflammation, we hypothesised that decreased gene expressions of VDR, PDIA3, retinoid receptors, and NR4A receptors will be exacerbated in individuals with schizophrenia who also have evidence of neuroinflammation.
Materials and Methods

Subjects
Brain tissue was provided by the New South Wales Brain Tissue Resource Centre, under ethical approval by the Human Research Ethics Committee at the University of New South Wales (HREC 12435). Brains from 37 cases (30 individuals diagnosed with schizophrenia and 7 with schizoaffective disorder) and 37 matched control individuals were selected. Case and control subjects were matched at a group level on brain tissue pH, age, post-mortem interval (PMI), hemisphere, and gender, and tissue from the DLPFC was dissected as previously described [51] . Low and high inflammation groups were determined based on a two-step cluster analysis of gene expression of markers of inflammation: IL1B, IL6, IL8, and serine protease inhibitor A3 [44] . The high inflammation control group was omitted in the current study due to a small sample size (n = 4), precluding meaningful statistical analysis.
Tissue Processing, RNA Extraction, and cDNA Synthesis Cortical tissues were crudely pulverised over dry ice, and 300 mg used for extraction of total RNA using TRIzol Reagent (Life Technologies Inc., Grand Island, NY, USA), as previously described [51] . The quantity and quality of RNA was determined by spectrophotometer (Nanodrop ND-1000, Thermo Scientific) and Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Three rounds of 3-µg total RNA was used for cDNA synthesis, using either SuperScript ® II or III First-Strand Synthesis System for RT-PCR (Life Technologies, Carlsbad, CA, USA). A seven-point serial dilution standard curve was created using 3 randomly selected schizophrenia cases and 3 randomly selected control cases.
Real-Time Quantitative Polymerase Chain Reaction mRNA for each gene of interest was amplified from cDNA using TaqMan
® Universal PCR Master Mix and the following Taqman probes (Thermo Fisher Scientific): VDR (Hs01045840_m1), PDIA3 (Hs00607126_m1; spanning exons 1-2 of most common isoforms); and the assays published in Corley et al. [43] RARA (Hs00940446_m1), RARB (forward/reverse: GCAGAGCGTGTA-ATTACCTTGAA/GTGAGATGCTAGGACTGTGCTCT), RARG (Hs01559234_m1), RXRA (Hs01067640_m1), RXRB (Hs00232774_m1), RXRG (Hs00199455_m1), NR4A1 (Hs00374226_m1), NR4A2 (Hs00428691_m1), and NR4A3 (Hs00545009_g1). mRNA expression was measured in triplicate using the 7900HT Fast Real Time PCR System (Applied Biosystems, Inc.). Florescent intensity values were normalised against the 
Statistical Analysis
All data were analysed using SPSS version 23. Subjects whose normalised expression values fell outside two standard deviations from the means were removed (average n = 3 per gene). Normalised expression values were tested for normality via the Kolmogorov-Smirnov test, and variables significantly deviating from a normal distribution were transformed via log or inverse transform to achieve Gaussian distributions. χ 2 tests were performed to determine whether sex and hemisphere were evenly distributed across the inflammation diagnostic groups. Normalised expression values for PDIA3 and NR4A3 were inverse transformed and RARG, RXRA, and RXRB results were transformed using log function to achieve Gaussian distributions within the inflammation diagnostic groups. Analyses of diagnostic group differences for all genes excluding VDR and PDIA3 mRNAs are previously described [43] . Pearson correlation tests were conducted between normalised gene expression and age, PMI, pH and RIN -variables showing significant correlations (p < 0.05) were included as covariates in downstream analyses. ANCOVAs were conducted using gene expression as the dependant variable and group as fixed factor plus relevant covariates, where p values <0.05 were considered significant. Post hoc testing by the Fisher least significant difference was performed for genes with significant ANCOVA results. All transcripts of interest were analysed for hemisphere and inflammation × diagnostic group differences.
Results
A cohort description and relevant demographics of subjects included in this study are presented in Table 1 . All analyses used mRNA extracted from either the left or right hemisphere, with the relative breakdown being 56.5% for the left and 43.5% for the right hemisphere in the low inflammation schizophrenia group, and an equal 50% left:right in the high inflammation schizophrenia group. In the low inflammation control group, 63.6% of samples were from the right hemisphere.
Correlation Analysis
Significant correlations between normalised gene expression and age, PMI or RNA integrity (RIN) were observed, whereby expression of the 3 NR4A genes correlated with age (p = 0.003-0.000002), the 3 RXRs and RARG and PDIA3 gene expression correlated with RIN (p = 0.012-0.00003), and some correlation with PMI were observed for RARA and RXRG (p = 0.031-0.032). Tissue pH differed amongst inflammation diagnostic groups (p = 0.001). Therefore, pH was included as a covariate in all statistical analyses, and age, PMI, and RIN were included in each ANCOVA where appropriate.
Hemisphere, Gender and Diagnostic Effects VDR and PDIA3 mRNA expressions were not significantly altered between diagnostic groups (Fig. 1) , and there were no differences in expression between sexes. Differential expression of the other nuclear receptors in control and schizophrenia diagnostic groups has previously been described [43] . There was no significant difference between the two hemispheres in the mRNA expression of PDIA3, but the expression of VDR mRNA in the right hemisphere was higher than that in the left (F[1, 70] = 5.216, p = 0.025) (Fig. 2a, b) . We found an interaction effect between diagnosis and hemisphere in mRNA 
Analysis of Inflammation × Diagnosis Group Differences in Gene Expression
We found significant differences amongst the three inflammation/diagnosis groups in the mRNA expression levels of RARG, RXRB, NR4A1, and NR4A3 (AN-COVA p = 0.021-0.0019) ( Table 2 ; Fig. 3 ). There was no significant effect of inflammation/diagnostic group on the mRNA expression levels of VDR, PDIA3, RARA, RARB, RXRA, RXRG, or NR4A2 (ANCOVA p values all >0.13).
To examine the directions of effect within each inflammatory subgroup, post hoc analysis revealed the RARG mRNA levels in the low inflammation schizophrenia (S-LO) group to be significantly lower than the low inflammation control (C-LO) group (p = 0.0023) and lower than the high inflammation schizophrenia (S-HI) group (p = 0.0018) (Fig. 3a) . In a similar pattern to RARG, RXRB mRNA levels in the S-LO group were found to be significantly lower than the C-LO group (p = 0.00045), but not significantly different from the S-HI group (p = 0.078) (Fig. 3b) .
In contrast to the pattern of changes in retinoid receptor mRNAs, the nuclear orphan receptors showed overall reduced expression in the S-HI group. The mRNA expression levels of NR4A1 in the S-HI group was significantly lower than both the S-LO group (p = 0.0197) and the C-LO group (p = 0.0019). The NR4A3 mRNA levels in the S-HI group were significantly lower than the S-LO group (p = 0.0062) and the C-LO group was also reduced at a trend level (p = 0.08).
Relationship of Gene Expression to Illness Onset, Duration or Medication Exposure
In order to determine whether gene expression was related to illness duration, onset or medication exposure, we performed correlation analysis within the schizophrenia group only. VDR and PDIA3 did not correlate with age of onset, duration of illness and medication. Results for all other retinoid receptors and NR4A receptors have previously been described [43] . As we previously found negative correlations between the 3 NR4A receptors and medication (chlorpromazine equivalent) dose, we added antipsychotic medication dose as a covariate, finding that NR4A1 and NR4A3 expression remained significantly different between S-HI and S-LO group after accounting for medication dose (Table 3) .
Discussion
This unique study focuses on vitamin A and D in the human post-mortem schizophrenia brain from a neuroinflammation perspective. Several studies have shown the neuroprotective qualities of vitamin D [22, 23, 52] . While the peripheral levels of vitamin D in individuals with schizophrenia have been extensively researched, this is the first study, to our knowledge, to measure the expression level of VDR in the brains of people with schizophrenia. We measured mRNA transcript levels of both the mem- brane-bound PDIA3 and cytosolic/nuclear VDR, but did not find any change in the overall level of either VDR mRNA with diagnosis. This suggests that the brains of individuals with schizophrenia may be able to respond normally to circulating vitamin D [23] [24] [25] , although alterations as a result of alternative splicing of the primary transcript, or from altered translation or post-translational modification were not explored here. Since it has been proposed that increased vitamin D levels may have the potential to reduce the risk of schizophrenia [10] , and we here showed that mRNA levels of VDRs are not changed in the brain of people with chronic schizophrenia, we would predict that augmenting vitamin D could be of potential preventative or therapeutic value as the intrinsic ability of the brain to respond to vitamin D may intact.
Our results suggest that brain VDRs are synthesised within a normal range in people with schizophrenia and that this level does not vary depending on inflammatory status, suggesting that regardless of inflammation status, vitamin D augmentation in schizophrenia may be of benefit. The literature suggests that increased levels of pro-inflammatory interleukins lead to a downregulation of retinoid receptors [53] [54] [55] , whereas activation of retinoid receptors results in attenuation of inflammation [56] [57] [58] [59] . This appears to be at odds with what we have observed in our study. Upon investigating the diagnostic inflammation groups, the mRNAs of two retinoid receptors, RXRB and RARG, as well as two orphan nuclear receptors, NR4A1 and NR4A3, were found to be significantly different amongst the 3 groups. With RXRB and RARG mRNAs being lower in the low inflammation schizophrenia group, it is unclear whether the change in expression of the retinoid receptors is leading to a change in inflammatory status or whether a change in inflammatory status is driving the changes in receptor expression. Previous work from our group has demonstrated reduced cognitive performance in individuals with schizophrenia with high inflammation [60] , thus it appears that high inflammatory peripheral activity may have functional consequences for the brain. Here, our data do not support the hypothesis that decreased signalling via lower retinoid receptor levels is a likely contributor to the high inflammation in schizophrenia, but in fact we find increased retinoid receptors in high inflammation schizophrenia, perhaps reflecting an attempt to compensate for putative tissue damage during neuroinflammatory processes, as suggested by grey matter volume reductions [46] and elevated astrogliosis in those with schizophrenia and high inflammation [61] .
NR4A1 and NR4A3 mRNAs showed a converse pattern to the retinoid receptors, with the high inflammation schizophrenia group showing decreased expression compared to the two low inflammation groups. Studies of macrophage and colon cancer cells have shown that NR4A receptors are typically upregulated with inflammation [62] [63] [64] . Additionally, overexpression of NR4A receptors in monocytes has been shown to reduce expression and production of pro-inflammatory cytokines [63] . This appears to be at odds with what we have observed in our cohort, although it may be explained by the relationship of NR4A receptors with aging: brain NR4A receptors decrease with age [43, 65, 66] and neuroinflammation is elevated with age [67] ; therefore, the decrease in NR4A receptors in the high inflammation schizophrenia group may be attributable to accelerated age-related changes associated with inflammation, the effect of which may be different in the brain compared to peripheral tissues. It may also be that the brain's ability to decrease retinoid receptors and increase NR4A receptors may reflect a lack of normal neuroinflammatory response, rendering the brain more vulnerable to deleterious effects of inflammation in those with schizophrenia.
In people with schizophrenia, the pathology of the left hemisphere is more severe than the right hemisphere [68] [69] [70] . In the same way as we see opposite patterns of retinoid receptor and NR4A receptors expression in the low inflammation groups in schizophrenia, we see opposite patterns in expression of these receptors between left and right hemispheres. NR4A2 expression is decreased in the right hemisphere in individuals with schizophrenia, whereas RARB is increased. This raises the question as to the regulation of transcription of these two receptor groups. It is known that RXRs heterodimerise with both RARs and NR4A receptors, but RARs and NR4A receptors do not heterodimerise to one another. Currently, there is no literature relating the RARs directly with the NR4As, in particular NR4A2, although a recent study has found that RARs regulate VDR transcription [71] . This hemispheric asymmetry supports findings of the left hemisphere being more pathologically impaired in schizophrenia compared to the right [68] [69] [70] . Thus, the decreased mRNA expression of VDR in the left hemisphere (regardless of diagnosis) could potentially contribute to reduced resilience of the left hemisphere in schizophrenia.
This work focuses on the overall mRNA expression level of the VDRs, retinoid receptors, and the NR4A receptors, but did not explore the levels of alternative spliced mRNA isoforms, protein levels or cellular location of these receptors or their wider interaction network, which is a limitation of the current study. 
Conclusion
We have shown that the mRNA expression of RARG and RXRB are reduced in schizophrenia individuals with low inflammation and this putative decreased signalling may suggest reduced retinoid-related neuroprotective actions in the absence of neuroinflammation in schizophrenia. In contrast, the mRNA expression of the 3 NR4A receptors is in the opposite pattern of change compared to RARG and RXRB. The reduction in NR4A1 and NR4A3 expression in the high inflammation schizophrenia group is consistent with the previously observed inverse relationship between NR4A receptors and age, as there is increased neuroinflammation with age. More studies on the role of nuclear receptors in neuroinflammation would be important steps towards potential targeted treatment of elevated inflammation in schizophrenia.
